INDIA at TCT 2025: TUXEDO-2 Trial Results
The TUXEDO-2 trial, led by Dr. Upendra Kaul, compared next-generation drug-eluting stents in diabetic patients.
In patients with diabetes and multivessel coronary artery disease (MVD), the ultra-thin biodegradable polymer sirolimus-eluting stent (Supraflex Cruz, SMT) demonstrated comparable procedural success and safety outcomes to the durable polymer everolimus-eluting stent (Xience, Abbott) when used alongside optimal medical therapy.
- Trial name: TUXEDO-2 (Ultra-Thin strUt versus XiencE in a Diabetic p!Opulation with Multi-vessel Disease–2) India study
- Focus: Comparing new-generation drug-eluting stents (DES) in an exclusively diabetic, high-risk population with extensive multivessel coronary disease
No direct quotes available.
Author's summary: TUXEDO-2 trial compares stents in diabetic patients.